mRNA Ä¡·á ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® ¸®Æ÷Æ® : ¿ëµµº°, À¯Çüº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)
mRNA Therapeutics Market Size, Share & Trends Analysis Report By Application (Rare Genetic Diseases, Oncology, Respiratory Diseases, Infectious Diseases), By Type (Prophylactic, Therapeutic), By End-use, By Region, And Segment Forecasts, 2024 - 2030
»óǰÄÚµå : 1474906
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2024³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 120 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,609,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,950 £Ü 10,055,000
Printable PDF (5-User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,949,000
Printable PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

mRNA Ä¡·á ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

Grand View ResearchÀÇ ÃֽЏ®Æ÷Æ®¿¡ µû¸£¸é ¼¼°èÀÇ mRNA Ä¡·á ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 313¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

2024-2030³âÀÇ CAGRÀº 17.05%·Î È®´ëÇÒ Àü¸ÁÀÔ´Ï´Ù. ½ÃÀå ¼ºÀåÀ» À̲ô´Â ÁÖ¿ä ¿äÀÎ Áß Çϳª´Â ´ç´¢º´, HIV, ¾Ï, CVD¿Í °°Àº ¸¸¼ºÁúȯ ¹× °¨¿°¼º ÁúȯÀÇ ¹ßº´·ü Áõ°¡ÀÔ´Ï´Ù. ¿¡º¼¶ó, µ¶°¨, HIV, ±×¸®°í ÃÖ±Ù¿¡´Â COVID-19¿Í °°Àº ¹ÙÀÌ·¯½º¼º ÁúȯÀ» ÅðÄ¡Çϱâ À§ÇÑ Ä¡·áÁ¦¿Í ¿¹¹æÁ¢Á¾¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡Çϸ鼭 ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, COVID-19 ¹ÙÀÌ·¯½º´Â ¸¹Àº Á¤ºÎ ±â°ü°ú ¹é½Å Á¦Á¶¾÷üµéÀÌ ÁÖ¸ñÇϰí ÀÖÀ¸¸ç, ½ÃÀå ¼ºÀåÀ» °¡¼ÓÈ­ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÃÀå È®´ë¸¦ °¡¼ÓÈ­ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ ¿©·¯ °ø±Þ¾÷üµéÀÌ ÀÓ»ó 1»ó°ú ÀÓ»ó 2»ó ´Ü°è¸¦ °áÇÕÇϰųª º¸°Ç ´ç±¹ÀÇ Çã°¡¸¦ º¸´Ù ½Å¼ÓÇÏ°Ô È¹µæÇÏ´Â µî »õ·Î¿î ±â¼úÀ» »ç¿ëÇÏ¿© ¿¹Ãø ±â°£ Áß Àü ¼¼°è¿¡¼­ ¹é½Å Á¢Á¾ ¿ë·®À» È®º¸ÇÒ ¼ö ÀÖ°Ô µÊ¿¡ µû¶ó ¾÷°è ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÷´Ü ±â¼úÀ» »ç¿ëÇÏ¿© mRNA ¹é½Å°ú Ä¡·áÁ¦´Â ±âÁ¸ ÀǾàǰ°ú ºñ±³ÇÏ¿© »ý»êµË´Ï´Ù. mRNAÀÇ »ýü³» Àü½Å Àü´ÞÀ» À§ÇÑ ÁöÁú ³ª³ëÀÔÀÚ ±¸¼ºÀÇ ¹ßÀüÀº ½ÃÀå È®´ë¿¡ À¯¸®ÇÑ Àü¸ÁÀ» Á¦°øÇϰí ÀÖÀ¸¸ç, ÀÌ´Â mRNAÀÇ »ýü³» Àü½Å Àü´ÞÀ» À§ÇÑ ÁöÁú ³ª³ëÀÔÀÚ ±¸¼ºÀÇ ¹ßÀü°ú ÇÔ²² ½ÃÀå È®´ë¿¡ À¯¸®ÇÑ Àü¸ÁÀ» Á¦°øÇÕ´Ï´Ù.

¿¹¸¦ µé¾î 2022³â 3¿ù ¹Ì±¹ ±¹¸³º¸°Ç¿ø(National Institutes of Health) »êÇÏ ±¹¸³¾Ë·¹¸£±â-Àü¿°º´¿¬±¸¼Ò(National Institute of Allergy and Infectious Diseases, NIAID)´Â ¸Þ½ÅÀú RNA(mRNA) Ç÷§ÆûÀÇ È°¼º ¼ººÐ¿¡ ±âÀÎÇÑ ¼¼ °¡Áö ÀáÀçÀû HIV ¹é½ÅÀ» Æò°¡ÇÏ´Â 1»ó ÀÓ»ó½ÃÇèÀ» ½ÃÀÛÇß½À´Ï´Ù. ÀÌ¿¡ µû¶ó ¼ö¿ä°¡ Áõ°¡ÇÏ¿© »ê¾÷ ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¶Ç ´Ù¸¥ Áß¿äÇÑ ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î Á¦¾àȸ»çµéÀº mRNA ±â¼ú¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö °ü·Ã ¿¬±¸°³¹ß(R&D) ±¸»ó°ú ÀÇ·á±â¼úÀÇ ¹ßÀü°ú °°Àº Ãß°¡ÀûÀÎ ¿äÀο¡ ÀÇÇØ ½ÃÀåÀÌ °ßÀ뵃 °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î Moderna¿Í AstraZeneca´Â mRNA¸¦ ÀÌ¿ëÇÑ ½É±Ù ÇãÇ÷ Ä¡·á(½É±ÙÀ¸·Î °¡´Â Ç÷·ù°¡ °¨¼ÒÇÏ¿© ½É±Ù¿¡ ÇÊ¿äÇÑ »ê¼Ò°¡ ºÎÁ·ÇØÁ® ¹ß»ýÇÏ´Â ½ÉÀå Áúȯ)¿¡ ´ëÇÑ °øµ¿¿¬±¸¸¦ ÁøÇàÇϰí ÀÖ½À´Ï´Ù. ¸¶Âù°¡Áö·Î, Arcturus Therapeutics´Â ½ÉÀ庴¿¡ ´ëÇÑ mRNA Ä¡·áÁ¦¸¦ ½ÃÇèÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÅõÀÚ´Â ÇâÈÄ ¼ö³â°£ ½ÃÀå ¼ºÀåÀ» º¸¿ÏÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

COVID-19 ÆÒµ¥¹ÍÀº mRNA ±â¼úÀÌ »ç¿ëµÇ´Â Áúº´ Áß ÇϳªÀÎ COVID-19 ¹é½ÅÀº ¾Ï Ä¡·á¿¡ ÁÖ·Î »ç¿ëµÇ¸ç, COVID-19 ¹é½ÅÀº mRNA ½ÃÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. mRNA ±â¾÷Àº Äڷγª¹ÙÀÌ·¯½ºÀÇ º¯ÀÌ ¹× ¹ÙÀÌ·¯½º º¯Á¾ È®»ê °¡´É¼ºÀ¸·Î ÀÎÇØ Â÷¼¼´ë COVID-19 ¹é½ÅÀ» °³¹ßÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 6¿ù ¹Ì±¹ ½ÄǰÀǾ౹(FDA)Àº Moderna COVID-19 ¹é½Å°ú Pfizer &BioNTech COVID-19 ¹é½ÅÀ» »ýÈÄ 6°³¿ù ¾î¸°ÀÌ¿¡°Ô COVID-19 ¿¹¹æ Á¶Ä¡·Î »ç¿ëÇϵµ·Ï ½ÂÀÎÇß½À´Ï´Ù. ±× °á°ú, COVID-19 ÆÒµ¥¹Í ±â°£ Áß ÀÌ·¯ÇÑ ±â¼úÀÇ »ç¿ëÀÌ Áõ°¡ÇÏ¿© »ê¾÷ ¼ºÀåÀ¸·Î À̾îÁú °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ ÃÖ±Ù ¼ö³â°£ ±â¾÷ÀÌ ÇöÀç ¿¬±¸°³¹ß ÇÁ·ÎÁ§Æ®¸¦ Áö¿øÇϱâ À§ÇØ Àü·«Àû Á¦ÈÞ¸¦ ¸Î´Â µî ÅëÇÕ Ãß¼¼°¡ µÎµå·¯Áö°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2021³â 2¿ù GlaxoSmithKline plc¿Í CureVac N.V.´Â ÇöÀç ÆÄÆ®³Ê½ÊÀ» ±â¹ÝÀ¸·Î COVID-19 Â÷¼¼´ë mRNA ¹é½ÅÀ» °³¹ßÇϱâ À§ÇØ ¹ÌÈ­ 1¾ï 5,236¸¸ ´Þ·¯ ±Ô¸ðÀÇ »õ·Î¿î °è¾àÀ» ¹ßÇ¥Çß½À´Ï´Ù. °¡ °³³ä Áõ¸íÀ» °ÅÃÄ ÀÓ»ó½ÃÇèÀ» °ÅÃÄ ÃÖÁ¾ÀûÀ¸·Î ½ÃÀå¿¡ Ãâ½ÃµÊ¿¡ µû¶ó ÀÌ Æ¯¼öÇÑ »ê¾÷ ºÎ¹®ÀÇ ÀÌÇØ°ü°èÀڵ鿡°Ô ºñÁî´Ï½º ±âȸ´Â ¾ÕÀ¸·Î Å©°Ô Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

mRNA Á¦¾à ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå ¿ëµµ ºñÁî´Ï½º ºÐ¼®

Á¦5Àå À¯Çü ºñÁî´Ï½º ºÐ¼®

Á¦6Àå ÃÖÁ¾ ¿ëµµ ºñÁî´Ï½º ºÐ¼®

Á¦7Àå Áö¿ªÀÇ ºñÁî´Ï½º ºÐ¼®

Á¦8Àå °æÀï ±¸µµ

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

mRNA Therapeutics Market Growth & Trends:

The global mRNA therapeutics market size is expected to reach USD 31.30 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 17.05% from 2024 to 2030. One of the main factors propelling the market growth is the rising incidence of chronic and infectious diseases like diabetes, HIV, cancer, and CVDs. The growing need for therapeutic drugs and vaccinations to combat viral illnesses like Ebola, influenza, HIV, and most recently COVID-19 is expected to fuel industry growth. The COVID-19 virus has been the focus of numerous government organizations and vaccine producers, and it is anticipated that this will accelerate market expansion.

Furthermore, the availability of vaccination doses around the world is projected to increase during the forecast period as a result of multiple suppliers using novel techniques, such as combining the phase 1 and phase 2 clinical trial stages and obtaining regulatory clearances more quickly from health agencies, thus contributing to the industry growth. With the use of cutting-edge technologies, mRNA vaccines and therapeutics are generated in comparison to conventional medications. These products are less expensive to produce, more powerful against infections, and have enhanced immunogenicity. A favorable outlook for market expansion is also being created by advancements in the compositions of lipid nanoparticles for in-vivo systemic delivery of mRNA.

For instance, in March 2022, The National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) launched a phase 1 clinical trial to assess three potential HIV vaccines using a messenger RNA (mRNA) platform due to its active component and direct the cells to make a protein (or perhaps a protein fragment) that stimulates an immune response using artificial mRNA created in a lab, which enhances the vaccine with more specificity as well as robust stability. Thus, it will increase the demand and further boost the industry growth.

As another significant growth-inducing element, pharmaceutical firms are spending on mRNA technology since they can combine numerous molecules into a therapeutic drug. The market is expected to be driven by additional factors, such as significant biotechnology-related research and development (R&D) initiatives and advancements in medical technology. For instance, Moderna and AstraZeneca are working together on a myocardial ischemia therapy using mRNA (a form of cardiac disease that develops when there is a decrease in blood flow to the heart, depriving the heart muscle of necessary oxygen). Similarly, mRNA treatments for heart disease are also being tested by Arcturus Therapeutics. Such investments are likely to supplement the market growth in the coming years.

The COVID-19 pandemic is anticipated to positively impact the industry growth. The COVID-19 vaccine is one of the diseases for which the mRNA technology is being used. In addition to its predominant use in cancer therapy, the COVID-19 vaccine is the main factor driving the market for mRNA. The mRNA firms are working hard to create COVID-19 vaccines for the next generation due to the coronavirus mutation and the potential spread of virus variants. For instance, in June 2022, The Food and Drug Administration approved the Moderna COVID-19 Vaccine and also the Pfizer & BioNTech COVID-19 Vaccine for use in children as young as 6 months old as COVID-19 preventative measures. As a result, the usage of these technologies is projected to increase during the COVID-19 pandemic and result in industry growth.

Additionally, there has been a discernible trend toward consolidation over the past few years, with players forming strategic alliances to support current R&D projects. For instance, in February 2021, building on their current partnership, GlaxoSmithKline plc and CureVac N.V. announced a new USD152.36 million agreement to create COVID-19 next-generation mRNA vaccines with the possibility for a multi-valent strategy to address numerous developing variations in a single vaccination. As additional mRNA-based therapeutic / vaccine leads exhibit proof-of-concept, go through clinical testing, and eventually hit the market, the opportunity for stakeholders involved in this specialized industry segment is likely to experience a significant increase in the predicted future.

mRNA Therapeutics Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Market Variables, Trends, & Scope

Chapter 4. Application Business Analysis

Chapter 5. Type Business Analysis

Chapter 6. End-use Business Analysis

Chapter 7. Regional Business Analysis by Application, Type, End-use

Chapter 8. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â